RISKS, REGULATION, AND REWARDS IN NEW DRUG DEVELOPMENT IN THE UNITED-STATES

被引：17

作者：

DIMASI, JA

机构：

[1] Tufts Univ, Boston, MA 02111, Ctr Study Drug Dev, 192 South St

来源：

REGULATORY TOXICOLOGY AND PHARMACOLOGY | 1994年 / 19卷 / 02期

关键词：

D O I：

10.1006/rtph.1994.1021

中图分类号：

DF [法律]; D9 [法律]; R [医药、卫生];

学科分类号：

0301 ; 10 ;

摘要：

[No abstract available]

引用

页码：228 / 235

页数：8

共 22 条

[1] BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES [J].

BIENZTADMOR, B ;

DICERBO, PA ;

TADMOR, G ;

LASAGNA, L .

BIO-TECHNOLOGY, 1992, 10 (05) :521-525

[2] DRUG DEVELOPMENT AND REGISTRATION IN JAPAN - THRESHOLD OF TRANSITION [J].

CURRIE, WJC .

JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (02) :100-108

[3] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142

[4] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1990 [J].

DIMASI, JA ;

BRYANT, NR ;

LASAGNA, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) :471-486

[5]

DIMASI JA, 1992, AM SOC CLIN PHARM TH

[6]

FAUST RE, 1983, REGULATION RESTRAINT

[7] A NEW LOOK AT THE RETURNS AND RISKS TO PHARMACEUTICAL RESEARCH-AND-DEVELOPMENT [J].

GRABOWSKI, H ;

VERNON, J .

MANAGEMENT SCIENCE, 1990, 36 (07) :804-821

[8]

GRABOWSKI HG, 1981, DRUGS HLTH EC ISSUES

[9]

Halliday RG, 1992, J PHARM MED, V2, P139

[10]

JAMES BG, 1977, FUTURE MULTINATIONAL

← 1 2 3 →